BofA upgraded Globus Medical (GMED) to Buy from Neutral with a price target of $91, up from $65. The company’s Q3 brought records in revenue, earnings and cash flow, the analyst tells investors in a research note. The firm cites Globus Medical’s ability to deliver compounded profits and cash flow for the upgrade. It says the stock’s valuation is “not stretched” at current levels.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Cautious Optimism: Hold Rating for Globus Medical Amid Strong Performance and Revenue Concerns
- Globus Medical upgraded to Buy from Hold at Truist
- Globus Medical’s Strong Q3 2025 Performance and Growth
- Closing Bell Movers: Expedia up 15%, Affirm up 12% on earnings beats
- Globus Medical reports Q3 adjusted EPS $1.18 consensus 77c